INTRODUCTION
The European nations have diverse political, economic, cultural, and geographic characteristics. These characteristics have, and will continue to have, important influences on the development and delivery of health care, which result in striking variations.
DEVELOPMENT OF THE EUROPEAN UNION
The European Union (EU) began as the European Economic Community (EEC) in 1967 with six founder members: Belgium, the Federal Republic of Germany, France, Italy, Luxembourg, and the Netherlands. The first expansion of the EEC was in 1973, when Denmark, Ireland, and the United Kingdom joined, followed by Greece in 1981 and then Portugal and Spain in 1986. 1 The composition and function of the EU have changed dramatically during the past 30 years along with several major political events. These include the fall of the Berlin wall (1989), the dissolution of the Union of Soviet States of Russia (1991), the division of Czechoslovakia (1993) , and the break-up of Yugoslavia into seven independent countries (war torn period, [1991] [1992] [1993] [1994] [1995] [1996] [1997] [1998] [1999] [2000] [2001] . The number of independent countries in Europe has almost doubled, and the number members of the EU has increased from 12 to 28 (Appendix Table A1 ).
There are 24 official languages in the EU, an additional five semiofficial languages, and 42 minority languages. Within some countries, such as Belgium, Romania, Spain, and Switzerland, multiple languages are spoken. This linguistic diversity creates a unique challenge for any unified analysis in which data definitions are essential. This is particularly relevant to collection of health care data.
EUROPEAN HEALTH CARE INFRASTRUCTURE AND LUNG CANCER SERVICES
A comparative assessment of health care infrastructure of European countries is an essential element of the assessment of health care provision and outcomes. A survey performed by a European Respiratory Society taskforce in 2011 collected information on health care infrastructure and the lung cancer pathway in 37 European countries. 2 The survey reported that, in 25 of the 37 countries, health care provision was funded through a form of National Health Service, which was based on income tax contributions or a mandatory health insurance program. This means that either the consultation at primary or secondary care is free for everyone or that a nominal fee is paid. Table 1 lists the different methods used to access a primary care physician, which remains the usual first point of contact for an individual with lung cancer. Greece and Cyprus, however, do not have universal coverage with primary care physicians, and an individual must choose to either pay to see a primary care physician privately or present themselves directly to secondary care. Additional inequality was identified in Bulgaria, where a primary care physician has a quota on the number of patients they can refer to secondary care each month. This introduces a delay in the diagnostic pathway. Variation was also seen in which specialist provided treatment of patients with lung cancer, with the exception of radiotherapy, which was provided universally by radiation oncologists. Chemotherapy was provided either by oncologists alone or by oncologists and respiratory physicians, sometimes in equal measure. Surgery was provided by a combination of pure thoracic surgeons, mixed cardiothoracic surgeons, and even general surgeons. Palliative care was not a recognized specialty in some countries and was provided by respiratory physicians, oncologists, and primary care physicians as well as by specific palliative care specialists. Not every country had multidisciplinary teams or lung cancer nurse specialists, and the definitions of these groups varied. Available resources, both diagnostic and therapeutic, were also highly variable. in 37 countries in 2011; a similar variation was seen for access to thoracic surgery. 2 
HISTORY OF CANCER DATA COLLECTION IN EUROPE
The use of data to evaluate trends in cancer incidence and outcome in European countries has undergone significant development in the past 25 years. In 1989, during his presidency of the EU, Francois Mitterrand initiated a health program on cancer prevention and patient information from which the EUROCARE studies have arisen.
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These studies use Europe-wide population-based cancer registries to calculate incidence, estimate prevalence, and report variation in survival. This information can be used for health care planning and to correctly allocate funding and resources. The first publication from EUROCARE was in 1995 and used data from 30 registries in 12 countries (1978) (1979) (1980) (1981) (1982) (1983) (1984) ; it demonstrated striking variations in cancer survival among countries. 4 Low survival rates were found in Eastern Europe, intermediate in Denmark and the United Kingdom, and higher in other Western European populations. An additional four monographs have reported EUROCARE data in the past 20 years, and each one reported population-based cancer registry data for specific time periods. The latest, which addressed those patients diagnosed between 1999 and 2007, was published in 2014. 5 There will inevitably be a delay in publication of results that are based on cancer survival, because 5-year survival remains the marker of cure in many cancer types; however, the delay has been reduced from 11 to 6 years. 6 With time, the numbers of countries and cancer registries involved with the project have increased; the EUROCARE-5 database contains approximately 22 million patients from 26 countries who were diagnosed with cancer between 1978 and 2007, with a follow-up date of December 31, 2008. 5 The survival differences first described in EUROCARE has narrowed, and improvement has been observed in those countries with a historically low survival rate. 6 A number of limitations exist with the EUROCARE data. In several countries, the coverage provided by cancer registration represents only a small proportion of the total population. 7, 8 Therefore the data cannot be assumed to be representative of the whole population. This is true for the Czech Republic, Germany, Italy, Poland, and Spain. 6, 9 In Italy, for example, there is better cancer registration in the more affluent north than in the poorer south, where cancer survival is known to be worse. 10 This will cause a bias in the results for Italy depicted in EUROCARE publications. Local criteria exist for registration of patients; in some countries, these are based on the pathologic confirmation of cancer, whereas other countries will accept registrations on the basis of a clinical diagnosis. This difference will generate a significant influence on the population denominator from which calculations of survival are based. Those patients without pathologic confirmation are frailer, have more advanced disease, and are unlikely to receive active cancer treatment.
11, The reliance on cancer registration via secondary care will also exclude those patients who remain under the care of primary care physicians. Furthermore, not all cancer registries accept diagnoses made on the basis of death certificates only. The absence of any occurrences with only a death certificate means that cancers with a short survival, like lung cancer, will not be adequately captured by the cancer registration process. This will create a systematic bias that causes survival figures to appear better than they are for the whole population of individuals with lung cancer. The EUROCARE authors acknowledge some concern that countries in Eastern Europe submit incomplete follow-up data, and this is particularly relevant for rapidly fatal cancers, like lung cancer. 12 Failure to record death in a timely manner, again, will lead to a survival bias. However, the main limitation of the EUROCARE database lies in the absence of clinical details, especially stage of disease and performance status. These two patient features are crucial to compare cancer outcome measures, such as resection rate and survival.
CANCER REGISTRIES ACROSS EUROPE
EUROCARE forms part of a number of inter-related projects that have been established since 1990 (Table 3) . [13] [14] [15] The European Network of Cancer Registries was established in 1990 within the framework of Europe Against Cancer Program funded by the EU.
3 It promotes collaboration between existing cancer registries, defines data standards, 13 offers training to registry personnel, and disseminates information thorough publication in peer review journals. EUROCOURSE (Europe Against Cancer: Optimization of the Use of Registries for Scientific Excellence in Research) was an EU-funded program designed to improve the networking between researchers and cancer registry personnel, and several other projects stem from this. EUROCHIP (European Cancer Health Indicator Project) is one of these projects, and one particular work package of EUROCHIP-3 is relevant here. The objective was to improve information about the collection and comparability of health indicators across Europe. Three key clinical indicators were chosen: stage at diagnosis, treatment delay, and compliance with cancer guidelines. The final report of EUROCHIP-3 (in 2013) states that only 15% of 103 participating cancer registries collect all three data items. Although 80% collect data about stage, less than 30% collect sufficient information about treatment and compliance. Furthermore, almost 25% had no interest in collection of additional data items. Lack of resources-both finances and qualified staffwere cited as reasons for this. 16 The disparity in the quality of data collection among cancer registries poses a significant challenge to the role of registries in epidemiologic and health care research. 17 The European Cancer Observatory is another example of a collaborative program developed at the International Agency ascopubs.org/journal/cci JCO™ Clinical Cancer Informatics 3 clinical interpretation of these data difficult. In the 2015 survey, only 17 countries routinely collected data about performance status; 15, about smoking history; 10, about comorbidity details; and only eight, about the socioeconomic status of the individual. In fact, details about the treatment given to a patient are not collected in nine of the 35 countries that took part in the survey.
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SPECIFIC NATIONAL LUNG CANCER AUDIT PROGRAMS
The Danish Lung Cancer Group was formed in 1991 and originally was a voluntary multidisciplinary group of representatives from across the lung cancer pathway. The group was born out of concern among Danish health care professionals about the poor prognosis for patients with lung cancer during preceding decades, 20, 21 and the primary goal was to improve survival and clinical outcomes. After clinical practice in 90 departments across Denmark was assessed, significant variation in practice was observed. 22 In response to this finding, the group began a two-pronged strategy to tackle these deficiencies. The first edition of the guidelines for clinical practice in lung cancer was published in 1998, and in the year 2000, data collection began at the national level. This data collection project tied in with the Danish National Indicator Project, which was established in 2000 as a continuous national program of data collection that was based on disease-specific standards, indicators, and prognostic factors for six disease groups (including lung cancer). A multidisciplinary team created the indicators and standards to which each institution should aspire, and data are sent electronically. There is a continuous process of evaluation of data and feedback to the individual units (clinicians and managers) about their current performance. 23 This generates an audit cycle and allows review of clinical practice and then prospective re-evaluation to improve the standard of care.
The Danish Lung Cancer Registry is an excellent example of how continuous data collection, with the correct political, financial, and professional support, can stimulate clinical improvements with real patient benefits. The database now contains detailed clinical information for more than 55,000 patients, and an annual report is published with information for the public as well as for health care professionals. There have been a number of improvements in outcome measures: the proportion of patients who had surgery within 14 days of referral has increased; 30-day postoperative mortality has decreased; the rates of pneumonectomy have decreased; and 1-, 3-, and 5-year postoperative survival rates all have increased. [22] [23] [24] Overall, 5-year survival has increased from 9.8% in 2003 to 12.1% in 2012, 22 and this is without any proven shift toward lower-stage disease in the lung cancer cohort. This implies that the improvement is a result of better or more active treatment, rather than earlier diagnosis. The observations that support this improvement include faster diagnostic work-up, more patients identified for treatment (estimated as 60% in 2000 and 85% in 2012), and shorter wait times to start treatment. The resection rates have remained stable, so there must have been an increase in oncology and palliative care provision during this time period. 22 After the publication of EUROCARE in 1995, an audit was distributed by the Clinical Effectiveness and Evaluation Unit of the Royal College of Physicians (London) to respiratory medicine departments in England, Wales, and Northern Ireland (in 1998). This collected both retrospective and prospective data about 1,600 patients in 48 hospitals. Information about presentation, investigations, and treatment, as well as the outcome at 6 months after bronchoscopy, was recorded. The report highlighted huge variations in clinical practice and delays along the diagnostic pathway. For example, the rate of surgical resection, excluding that of small-cell lung cancer, ranged from 3% to 33%, and chemotherapy for only small-cell lung cancer ranged from 14% to 100%. 25 A need for political leadership on cancer care within the National Health Service (NHS) had been acknowledged, and the NHS Cancer Plan was implemented in 2000. 26 Some of the key features of this plan were the instigation of multidisciplinary teams to manage occurrences of suspected and proven cancer; the enforcement of wait time targets for points on the pathway; the process of peer review; and anonymous data collection. This effort was fol- anonymously collect and analyze data about individuals with lung cancer. An online data collection tool allowed hospitals to submit data about their patients individually or en masse. After a pilot phase in 2004, credibility within the clinical community increased gradually, as did data completeness (performance status and stage are now recorded for more than 90% of cases), particularly after the data set was validated in 2011. 29 Participation became universal despite the initially nonmandatory status of the audit. Outputs from the audit include more than 40 peerreviewed papers; hundreds of abstracts delivered at regional, national, and international meetings; 10 annual reports; and a mesotheliomaspecific report that was based on a 3-year period of data. 30 These outputs have charted a gradual improvement in both the process and the outcome for patients with lung cancer; highlights include an almost doubling of the (curative) surgical resection rate and an improvement in 5-year survival from 7% (in 1995) to a predicted 16% for patients diagnosed in 2013. 31 A persistent theme in all of these outputs is the variation in standards of care across different organizations, 30, [32] [33] [34] and the use of statistical methods has shown that case-mix does not explain the majority of these variations. The National Lung Cancer Audit is now the largest clinical data set for patients with lung cancer and includes key patient features, such as performance status, comorbidity, stage, and socioeconomic status. This level of clinical detail makes it a powerful resource for research. [35] [36] [37] [38] [39] [40] [41] In part due to the success of the National Lung Cancer Audit, interest in the use of data to improve outcomes in other cancers led to the development of the Cancer Services and Outcomes Data Set in England by the National Cancer Registration and Analysis Service. Monthly submission to the data set is mandatory for all providers of cancer care. The service is able to link the data set with a number of other detailed data sets that cover hospital admissions (Hospital Episode Statistics), systemic treatment (Systemic Anti-Cancer Data Set, derived from electronic prescribing), and radiotherapy (Radiotherapy Treatment Data Set, taken from radiotherapy linear accelerators).
There are several similarities in the development of the national audit programs for lung cancer in Denmark and the United Kingdom: Both countries have an NHS, by which health care is essentially free at the point of access. Both countries were shown, from the 1990s, to have worse survival compared with other countries that had similarly advanced health care systems. In both countries, data entry was voluntary initially; with regular feedback to the clinicians, the benefit of data collection was clearly demonstrated, sowith political motivation-collection and feedback are now mandatory. This regular feedback is delivered in a manner not to highlight struggling centers but to identify areas of need and then provide the support required to improve the standard of care and reduce inequality. An example is the Improving Lung Cancer Outcomes Program. 42 In conclusion, the use of data to drive improvements in care for people with lung cancer has been shown to be a powerful tool, but survival remains poor. 43 The creation of a pan-European data set is a significant challenge but one that, if done correctly, will expose variation in practice, identify best practices, show where improvement is needed, and guide investment in resources. It is essential that data are comparable and that requires use of the same or similar data definitions and reports about the same population to avoid any systematic bias. It is time to define a minimum agreed pan-European data set and to use the iterative approach applied by Denmark and the United Kingdom: universal stakeholder engagement, investment of time and infrastructure, the publication of results at the local level, and creation of a positive audit cycle that leads to improvements in patient care and lung cancer outcomes. The European Respiratory Society has sponsored a number of taskforces with this aim in mind. A minimum data set has been created as part of a statement paper that has an expected publication date of early 2018 (Rich A, et al: submitted for publication). 
